MADRID, 10 Nov. (EUROPA PRESS) -

Almirall obtained a net profit of 10.9 million euros in the first nine months of the year, compared to losses of 39.4 million euros registered in the same period of 2021, as reported by the company on Thursday, which has specified that its normalized net result reached 32.7 million euros, in contrast to the losses of 61.5 million in 2021.

The biopharmaceutical has indicated that the comparison of its results with last year is affected by a divestment of products in the first half of 2021 and by the deferred income of AstraZeneca that ended last year.

Almirall's 'core' sales, which exclude the contribution of AstraZeneca and Covis, increased by 5.3% between January and September, to 633.8 million euros, thanks to the products recently launched by the company and the good behavior of the dermatology business in Europe, which showed year-on-year growth of 21%.

For its part, the 'core' Ebitda of Almirall (excluding AstraZeneca and Covis) fell by 18.4% between January and September, to 134 million euros, while the 'core' gross margin stood at 66.5 %, in line with the company's expectations for this year and the next.

Following these results, Almirall has confirmed its financial estimates for 2022. "We are pleased with the good business momentum we have seen in the third quarter, with our growth engines showing strong growth. Our core business continues to perform well, in line with our expectations, which places us on target to achieve our financial estimates for 2022", highlighted Almirall's chairman and interim CEO, Carlos Gallardo.

Gallardo will act as interim CEO while Almirall finds the definitive candidate to succeed Gianfranco Nazzi, who recently left the biopharmaceutical company.

"The company can count on my total dedication and commitment and that of the entire Almirall executive team throughout the search for the new CEO, in our exciting journey towards leadership in medical dermatology", added Gallardo.